|Targets||HMG-CoA Reductase (HMGCR)|
|Description||SR 12813 is a pregnane X receptor (PXR) agonist (EC50 = 200 and 700 nM for human and rabbit PXR, respectively) that activates the farnesoid X receptor (FXR) at μM concentrations. SR 12813 exhibits hypocholesterolaemic activity via enhancing the degradation of HMG-CoA reductase.|
|Brife Description||PXR agonist|
|Purity||≥99% by HPLC|
|Synonyms||SR 12813; SR12813; SR-12813; [[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-phosphonic acid tetraethyl ester; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol|
Fluvastatin Sodium inhibits HMG-CoA reductase activity with IC50 of 8 nM.
Rosuvastatin, also called as ZD 4522 or Crestor, a synthetic statin, in the phase III HYDRA trial for Hypercholesterolaemia, is a competitive inhibitor of HMG-C...
Atorvastatin, a HMG-CoA reductase inhibitor, could be used to reduce cholesterol and prevent cardiovascular related disease.
Meglutol is a hypolipidemic agent which inhibits the activity of hydroxymethylglutarryl CoA reductases.
Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol.
SR 12813 is a pregnane X receptor (PXR) agonist (EC50 = 200 and 700 nM for human and rabbit PXR, respectively) that activates the farnesoid X receptor (FXR) at ...
Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase (HMGCR) with IC50 of 8 nM. It belongs to a class of the statin drug and is ...
Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself.